New imaging tracer could reveal hidden secrets of breast cancer
NCT ID NCT03846167
First seen Mar 04, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests a new PET imaging agent called 18F-FluorThanatrace to measure PARP-1 activity in breast cancer tumors. About 50 adults with known or suspected breast cancer will receive an injection of the tracer and undergo one or two PET/CT scans. The goal is to see how well the tracer highlights cancer and whether changes in activity can predict response to therapy. This is an observational imaging study, not a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.